Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202)

被引：0
|
作者：
Toshirou Nishida
Kuniaki Shirao
Akira Sawaki
Masato Koseki
Takeshi Okamura
Atsushi Ohtsu
Toshiro Sugiyama
Kunihisa Miyakawa
Seiichi Hirota
机构：
[1] Osaka University Graduate School of Medicine,Department of Surgery
[2] National Cancer Center Hospital,Department of Medical Oncology
[3] Aichi Cancer Center Hospital,Department of Gastroenterology
[4] National Hospital Organization Kure Medical Center,Department of Surgery
[5] National Kyushu Cancer Center,Department of Gastroenterological Surgery
[6] National Cancer Center Hospital East,Division of Gastrointestinal Oncology/Digestive Endoscopy
[7] Hokkaido University Graduate School of Medicine,Department of Gastroenterology
[8] National Cancer Center Hospital,Diagnostic Radiology Division
[9] Hyogo College of Medicine,Department of Surgical Pathology
来源：
International Journal of Clinical Oncology | 2008年 / 13卷
关键词：
Gastrointestinal stromal tumor; Imatinib; Phase II;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Phase I/II study of arsenic trioxide (Trisenox) in combination with imatinib mesylate (Gleevec, STI571) in patients with Gleevec-resistant chronic myelogenous leukemia in chronic phase.
    Mauro, MJ
    Deininger, MW
    O'Dwyer, ME
    Maziarz, RT
    Walker, T
    Kurilik, G
    Druker, BJ
    BLOOD, 2002, 100 (11) : 781A - 781A
  • [42] Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study
    Yamazaki, Naoya
    Kiyohara, Yoshio
    Uhara, Hisashi
    Uehara, Jiro
    Fujimoto, Manabu
    Takenouchi, Tatsuya
    Otsuka, Masaki
    Uchi, Hiroshi
    Ihn, Hironobu
    Minami, Hironobu
    CANCER SCIENCE, 2017, 108 (06): : 1223 - 1230
  • [43] Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate
    Joensuu, H.
    De Braud, F.
    Coco, P.
    De Pas, T.
    Putzu, C.
    Spreafico, C.
    Bono, P.
    Bosselli, S.
    Jalava, T.
    Laurent, D.
    Casali, P. G.
    ANNALS OF ONCOLOGY, 2008, 19 (01) : 173 - 177
  • [44] A phase II study of sorafenib in patients with metastatic or unresectable gastrointestinal stromal tumors with failure of both imatinib and sunitinib: A KGSG study.
    Ryu, M.
    Park, S. H.
    Ryoo, B.
    Im, S.
    Kwon, H.
    Lee, S. S.
    Park, S. R.
    Kang, B. W.
    Kang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors
    Singh, Arun S.
    Hecht, J. Randolph
    Rosen, Lee
    Wainberg, Zev A.
    Wang, Xiaoyan
    Douek, Michael
    Hagopian, Anahis
    Andes, Rachel
    Sauer, Lauren
    Brackert, Sandra R.
    Chow, Warren
    DeMatteo, Ronald
    Eilber, Fritz Christian
    Glaspy, John A.
    Chmielowski, Bartosz
    CLINICAL CANCER RESEARCH, 2022, 28 (01) : 84 - 94
  • [46] Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: a real-world, multicenter, observational study
    Yang, Weili
    Qian, Haoran
    Yang, Litao
    Wang, Pengfei
    Qian, Hailong
    Chu, Binbin
    Liu, Zhuo
    Sun, Jingyu
    Wu, Dan
    Sun, Lifeng
    Zhou, Wenqiang
    Hu, Jingwei
    Chen, Xiaolei
    Shou, Chunhui
    Ruan, Lingxiang
    Zhang, Yunyun
    Yu, Jiren
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [47] Safety, PK and preliminary efficacy of talazoparib in Japanese patients with advanced solid tumors; Phase 1 Study
    Naito, Yoichi
    Kuboki, Yasutoshi
    Ikeda, Masafumi
    Harano, Kenichi
    Matsubara, Nobuaki
    Toyoizumi, Shigeyuki
    Oishi, Masayo
    Hori, Natsuki
    Nagasawa, Takashi
    Kogawa, Takahiro
    ANNALS OF ONCOLOGY, 2019, 30
  • [48] Phase II study of paclitaxel in patients with advanced gastrointestinal stromal tumor (GIST) after failure of at least both imatinib and sunitinib
    Cho, H.
    Ryu, M-H.
    Kim, B. J.
    Park, Y.
    Na, Y-S.
    Ma, J.
    Beck, M. Y.
    Kang, Y-K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [49] Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib mesylate.
    Blanke, C. D.
    Demetri, G. D.
    Von Mehren, M.
    Heinrich, M. C.
    Eisenberg, B. L.
    Fletcher, J.
    Corless, C. L.
    Wehrle, E.
    Sandau, K. B.
    Joensuu, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 526S - 526S
  • [50] Efficacy and safety of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2 multicenter, randomized, openlabel study in China.
    Li, Jian
    Zhang, Jun
    Zhang, Yanqiao
    Qiu, Haibo
    Zhou, Yanbing
    Zhou, Yongjian
    Zhang, Xinhua
    Zhou, Ye
    Zhu, Yuping
    Li, Yong
    Wang, Ming
    Shen, Kuntang
    Tao, Kaixiong
    Wu, Xin
    Wang, Haijiang
    Zhang, Bo
    Ling, Jiayu
    Ye, Yingjiang
    Dong, Juan
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 803 - 803
12345